Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$160.05 USD
-1.55 (-0.96%)
Updated May 31, 2024 04:00 PM ET
After-Market: $159.83 -0.22 (-0.14%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Brokerage Reports
Krystal Biotech, Inc. [KRYS]
Reports for Purchase
Showing records 61 - 66 ( 66 total )
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Important Box Checked; First cGMP Facility Up and Running; Significant KB-103 Data Update Mid-2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
First In-House GMP Facility Completed; All Eyes on KB103 Data Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
First In Class, Topical Gene Therapy Moving Quickly Towards Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Results; First Topical Gene Therapy is Moving Quickly to Phase 3; Target Reduced to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
First KB103 Look Impresses; Target increased to $35.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Krystal Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Building a Derm Focused Gene Therapy Model; Initiating at Buy and $32 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J